Eton Pharmaceuticals signs exclusive US license deal with Aquestive for Libervant seizure rescue film
Bitget2026/10/14 10:50- Eton Pharmaceuticals signed an exclusive U.S. license and supply deal with Aquestive for LIBERVANT (diazepam) buccal film for seizure clusters.
- Eton targets an April 2027 commercial launch, contingent on final FDA approval.
- Full approval for patients 12 and older is expected after VALTOCO orphan exclusivity ends on Jan. 10, 2027.
- A separate NDA to add ages 6-11 has a PDUFA action date of March 29, 2027.
- Deal adds a neurology platform for Eton in a U.S. seizure rescue market estimated at more than $450 million annually.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Crypto prices
More
